CTL induction by cross-priming is restricted to immunodominant epitopes

European Journal of Immunology

Volumn 39, Issue 3, 2009, Pages 704-716

  Pavelic, Viktor ^a   Matter, Matthias ^a,b   Mumprecht, Sabine ^a   Breyer, Isabel ^a   Ochsenbein, Adrian F ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

CD8 T cells; Cross presentation priming; Tumor immunology

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; EPITOPE; GAMMA INTERFERON; LYMPHOCYTIC CHORIOMENINGITIS VIRUS GLYCOPROTEIN 33; LYMPHOCYTIC CHORIOMENINGITIS VIRUS NUCLEOPROTEIN 118; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NUCLEOPROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; HAPLOTYPE; IMMUNE RESPONSE; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR IMMUNITY; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DENDRITIC CELL; GENETIC TRANSFECTION; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIGENS, VIRAL; CELL LINE, TUMOR; CROSS-PRIMING; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNODOMINANT EPITOPES; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 64049105773     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200838901     Document Type: Article

References (52)

1. Chen, L., Ashe, S., Brady, W. A., Hellstrom, I., Hellstrom, K. E., Ledbetter, J. A., McGowan, P. and Linsley, P. S., Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992. 71: 1093-1102.
2. Ochsenbein, A. F., Sierro, S., Odermatt, B., Pericin, M., Karrer, U., Hermans, I. F., Hemmi, S. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001. 411: 1058-1064.
3. Denfeld, R. W., Dietrich, A., Wuttig, C., Tanczos, E., Weiss, J. M., Vanscheidt, W., Schopf, E. and Simon, J. C., In situ expression of B7 and CD28 receptor families in human malignant melanoma: Relevance for T-cell-mediated anti-tumor immunity. Int. J. Cancer 1995. 62: 259-265.
4. Kündig, T. M., Bachmann, M. F., DiPaolo, C., Simard, J. J. L., Battegay, M., Lother, H., Gessner, A. et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 1995. 268: 1343-1347.
5. Neijssen, J., Herberts, C., Drijfhout, J. W., Reits, E., Janseen, L. and Neefjes, J., Cross-presentation by intercellular peptide transfer through gap junctions. Nature 2005. 434: 83-88.
6. Jensen, P. E., Recent advances in antigen processing and presentation. Nat. Immunol. 2007. 8: 1041-1048.
7. Wolkers, M. C., Brouwenstijn, N., Bakker, A. H., Toebes, M. and Schumacher, T. N., Antigen bias in T cell cross-priming. Science 2004. 304: 1314-1317.
8. Shen, L. and Rock, K. L., Cellular protein is the source of cross-priming antigen in vivo. Proc. Natl. Acad. Sci. USA 2004. 101: 3035-3040.
9. +T cell cross-priming via transfer of proteasome substrates. Science 2004. 304: 1318-1321.
10. Groh, V., Li, Y. Q., Cioca, D., Hunder, N. N.,Wang,W., Riddell, S. R., Yee, C. and Spies, T., Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc. Natl. Acad. Sci. USA 2005. 102: 6461-6466.
11. Albert, M., Sauter, B. and Bhardwaj, N., Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTL. Nature 1998. 392: 86-89.
12. + dendritic subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 2002. 195: 1289-1302.
13. Heath, W. R., Belz, G. T., Behrens, G. M., Smith, C. M., Forehan, S. P., Perish, I. A., Davey, G. M. et al., Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 2004. 199: 9-26.
14. Kuchtey, J., Chefalo, P. J., Gray, R. C., Ramachandra, L. and Harding, C. V., Enhancement of dendritic cell antigen cross-presentation by CpG DNA involves type I IFN and stabilization of class I MHC mRNA. J. Immunol. 2005. 175: 2244-2251.
15. Maurer, T., Heit, A., Hochrein, H., Ampenberger, F., O'Keefe, M., Bauer, S., Lipford, G. B. et al., CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur. J. Immunol. 2002. 32: 2356-2364.
16. +CTL to cause tumor eradication. J. Immunol. 2004. 173: 6753-6759.
17. van Mierlo, G., den Boer, A., Medema, J. P., van der Voort, E., Fransen, M., Offringa, R., Melief, C. J. and Toes, R., CD40 stimulation leads to effective therapy of CD40- tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl. Acad. Sci. USA 2002. 99: 5561-5566.
18. Cioca, D., Deak, E., Cioca, F. and Paunescu, V., Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+T cells. J. Immunother. 2006. 29: 41-52.
19. Schnurr, M., Chen, Q., Shin, A., Chen, W., Toy, T., Jenderek, C., Green, S. et al., Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 2005. 105: 2465-2472.
20. Wolkers, M., Stoetter, G., Vyth-Dreese, F. A. and Schumacher, T., Redundancy of direct priming and cross-priming in tumo-specific CD81T cell responses. J. Immunol. 2001. 167: 3577-3584.
21. Matter, M., Pavelic, V., Pinschewer, D. D., Mumprecht, S., Eschli, B., Giroglou, T., von Laer, D. and Ochsenbein, A. F., Decreased tumor surveillance after adoptive T-cell therapy. Cancer Res. 2007. 67: 7467-7476.
22. Beyer, W. R., Miletic, H., Ostertag, W. and von Laer, D., Recombinant expression of lymphocytic choriomeningitis virus strain WE glycoproteins: A single amino acid makes the difference. J. Virol. 2001. 75: 1061-1064.
23. Novellino, L., Castelli, C. and Parmiani, G., A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 2005. 54: 187-207. Epub 2004 Aug 2007.
24. Blattman, J. N., Antia, R., Sourdive, D. J., Wang, X., Kaech, S. M., Murali-Krishna, K., Altman, J. D. andAhmed, R., Estimating the precursor frequency of naive antigen-specific CD8 T cells. J. Exp. Med. 2002. 195: 657-664.
25. +T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J. Immunol. 2000. 164: 3095-3101.
26. +T cells to cause immunopathology. J. Exp. Med. 1998. 187: 763-774.
27. +CTL following exposure to vaccinia virus via different routes. J. Immunol. 2002. 169: 4222-4229.
28. Ehl, S., Aichele, P., Ramseier, H., Barchet, W., Hombach, J., Pircher, H., Hengartner, H. and Zinkernagel, R., Antigen persistence and time of T-cell tolerization determine the efficacy of tolerization protocols for prevention of skin graft rejection. Nat. Med. 1998. 4: 1015-1019.
29. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D. and Levitsky, H., Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994. 264: 961-965.
30. Sotomayor, E. M., Borrello, I., Rattis, F. M., Cuenca, A. G., Abrams, J., Staveley-O'Carroll, K. and Levitsky, H. I., Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 2001. 98: 1070-1077.
31. + T cells by viral and tumor antigens is a robust phenomenon. Eur. J. Immunol. 2004. 34: 194-199.
32. Hombach, J., Pircher, H., Tonegawa, S. and Zinkernagel, R. M., Strictly transporter of antigen presentation (TAP)-dependent presentation of an immunodominant cytotoxic T lymphocyte epitope in the signal sequence of a virus protein. J. Exp. Med. 1995. 182: 1615-1619.
33. Probst, H. C., Tschannen, K., Gallimore, A., Martinic, M., Basler, M., Dumrese, T., Jones, E. and van den Broek, M. F., Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. J. Immunol. 2003. 171: 5415-5422.
34. Basta, S., Stoessel, R., Basler, M., van den Broek, M. F. and Groettrup, M., Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J. Immunol. 2005. 175: 796-805.
35. +T cell response to a subdominant tumor antigen epitope. J. Immunol. 2005. 175: 700-712.
36. Kedl, R. M., Kappler, J. W. and Marrack, P., Epitope dominance, competition and T cell affinity maturation. Curr. Opin. Immunol. 2003. 15: 120-127.
37. Wong, P. and Pamer, E. G., Feedback regulation of pathogen-specific T cell priming. Immunity 2003. 18: 499-511.
38. Spiotto, M. T., Yu, P., Rowley, D. A., Nishimura, M. I., Meredith, S. C., Gajewski, T. F., Fu, Y. X. and Schreiber, H., Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002. 17: 737-747.
39. Kurts, C., Miller, J. F., Subramaniam, R. M., Carbone, F. R. and Heath, W. R., Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J. Exp. Med. 1998. 188: 409-414.
40. Morgan, D. J. H. K. and Sherman, L., Antigen concentration and precursor frequency determine the rate of CD81T cell tolerance to peripherally expressed antigens. J. Immunol. 1999. 163: 723-727.
41. Spiotto, M. T., Rowley, D. A. and Schreiber, H., Bystander elimination of antigen loss variants in established tumors. Nat. Med. 2004. 10: 294-298.
42. +T cell responses. Proc. Natl. Acad. Sci. USA 2007. 104: 13426-13431.
43. Di Simone, C., Zandonatti, M. A. and Buchmeier, M. J., Acidic pH triggers LCMV membrane fusion activity and conformational change in the glycoprotein spike. Virology 1994. 198: 455-465.
44. Borbulevych, O., Baxter, T. K., Yu, Z., Restifo, N. P. and Baker, B. M., Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J. Immunol. 2005. 174: 4812-4820.
45. Busch, D. and Pamer, E., MHC class I/peptide stability: implications for immunodominance, in vitro proliferation, and diversity of responding CTL. J. Immunol. 1998. 160: 4441-4448.
46. Oukka, M., Manuguerra, J. C., Livaditis, N., Tourdot, S., Riche, N., Vergnon, I., Cordopatis, P. et al., Protection against lethal viral infection by vaccination with nonimmunodominant peptides. J. Immunol. 1996. 157: 3039-3045.
47. +T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 2002. 99: 16168-16173.
48. Pircher, H., Bürki, K., Lang, R., Hengartner, H. and Zinkernagel, R. M., Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 1989. 342: 559-561.
49. Lutz, M. B., Kukutsch, N., Ogilvie, A. L., Rossner, S., Koch, F., Romani, N. and Schuler, G., An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 1999. 223: 77-92.
50. Ehl, S., Nuesch, R., Tanaka, T., Myasaka, M., Hengartner, H. and Zinkernagel, R. M., A comparison of efficacy and specificity of three NK depleting antibodies. J. Immunol. Methods 1996. 199: 149-153.
51. Aichele, P., Kyburz, D., Ohashi, P. S., Odermatt, B., Zinkernagel, R. M., Hengartner, H. and Pircher, H., Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. Proc. Natl. Acad. Sci. USA 1994. 91: 444-448.
52. Seiler, P., Brundler, M. A., Zimmermann, C., Weibel, D., Bruns, M., Hengartner, H. and Zinkernagel, R. M., Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: Implications for passive and active immunization. J. Exp. Med. 1998. 187: 649-654.